NewEdge Wealth LLC Lowers Holdings in IDEXX Laboratories, Inc. $IDXX

NewEdge Wealth LLC lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.9% in the third quarter, HoldingsChannel reports. The fund owned 2,968 shares of the company’s stock after selling 880 shares during the quarter. NewEdge Wealth LLC’s holdings in IDEXX Laboratories were worth $1,896,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. WealthCollab LLC acquired a new position in IDEXX Laboratories during the second quarter worth approximately $30,000. J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $31,000. Armstrong Advisory Group Inc. grew its stake in shares of IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after buying an additional 19 shares during the period. Salomon & Ludwin LLC acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $35,000. Finally, Greykasell Wealth Strategies Inc. acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $35,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories News Roundup

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Analyst support remains a tailwind — multiple firms continue to rate IDXX favorably (Jefferies, BTIG, Barclays among others) and the consensus remains a “Moderate Buy” with a material above‑current price target consensus. That analyst backdrop can support buying interest. Read More.
• Neutral Sentiment: Company fundamentals: IDXX reported a slight EPS miss (by $0.01) for the most recent quarter but beat on revenue (+14% y/y) and provided FY‑2026 EPS guidance of $14.29–$14.80 — guidance is above many near‑term expectations, which is generally constructive for the stock. Read More.
• Neutral Sentiment: Re‑rating narrative: recent commentary (Conestoga/InsiderMonkey, Yahoo syndicated pieces) argues IDXX shares are re‑rating toward historical averages — this is discussion‑driven and could help multiple investors re‑allocate into the name if the argument gains traction. Read More.
• Neutral Sentiment: Comparisons in the sector: valuation/sector pieces (e.g., Zacks comparing SONVY vs IDXX) may influence relative‑value flows but don’t present new company‑specific catalysts. Read More.
• Neutral Sentiment: Short‑interest data posted for February appears to show zero shares / zero days‑to‑cover (likely a reporting anomaly). That suggests no clear short‑squeeze pressure at present but verify with exchange short‑interest releases.
• Negative Sentiment: Insider selling: multiple execs disclosed sizable sales on Feb 17 — Director Sophie Vandebroek sold 1,464 shares (~$628.62 avg) and EVP Michael Erickson sold 5,371 shares (~$627.38 avg). Large insider sales can be read as signal of personal liquidity/positioning and may weigh on near‑term sentiment. Read More. Read More.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the transaction, the director owned 648 shares in the company, valued at $407,345.76. The trade was a 69.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael G. Erickson sold 5,371 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the completion of the transaction, the executive vice president directly owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. The trade was a 29.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 18,180 shares of company stock valued at $11,626,996 in the last quarter. Company insiders own 0.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on IDXX shares. UBS Group reduced their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. Barclays decreased their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Jefferies Financial Group reiterated a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Finally, Wall Street Zen raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 7th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $635.66 on Friday. The firm has a market capitalization of $50.76 billion, a PE ratio of 48.64, a price-to-earnings-growth ratio of 3.87 and a beta of 1.67. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The stock’s 50 day moving average price is $677.74 and its 200 day moving average price is $669.01. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the business earned $2.53 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.